Amlocor

Quick links to important sections

Amlocor

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlocor

Property Description
Active ingredient Amlodipine besylate
Form Oral tablet (Single-ingredient product)
Pharmacological class Calcium Channel Blocker (Dihydropyridine derivative)
General purpose Management of high blood pressure and vascular constriction
Origin Synthetic compound

Amlocor: Identity and Pharmacological Classification

Amlocor is a prescription-only medicine whose core component is the active ingredient Amlodipine besylate, classified as a synthetic compound. It belongs to the high-level pharmacological class of Calcium Channel Blockers (CCBs), specifically the Dihydropyridine derivative subclass, a classification consistently utilized in clinical practice. This means the drug is fundamentally designed to reduce tension in the circulatory system.

This classification indicates that Amlodipine is designed to modulate the movement of calcium ions, primarily within the smooth muscle of blood vessel walls. Its efficacy for reducing systemic vascular resistance is established within the field of pharmacology. The drug is recognized for its effectiveness in providing sustained management for chronic conditions involving vascular tone in adult patients.

What is the Active Substance in Amlocor and its Form?

The active substance is Amlodipine besylate, a distinct salt of the compound Amlodipine chosen for its pharmaceutical stability and bioavailability. Amlocor is supplied as a single-ingredient product in the dosage form of an oral tablet for consumption.

The tablets are composed of the active ingredient plus inactive excipients—substances necessary to create the tablet's bulk and structure. This preparation is for oral administration, ensuring that the drug is absorbed through the digestive system to exert its sustained effect on the circulatory system throughout the body. Prescribing information describes its properties as a once-daily maintenance therapy for cardiovascular patients.

General Purpose: Modulating Cardiovascular Function

The general purpose of Amlocor is to achieve persistent vessel relaxation to reduce the workload on the heart and circulatory system. This mechanism is intended to help reduce elevated blood pressure, a common use scenario for this class of medicine.

By promoting the widening of blood vessels, a process known as vasodilation, Amlodipine reduces the resistance that blood encounters as it flows through the arteries. This reduction in peripheral vascular resistance is the fundamental physiological outcome, contributing to the overall management and stability of cardiovascular health and is recognized for its role in maintaining stable circulatory conditions.

Regulatory References

  1. Amlodipine - StatPearls - NCBI Bookshelf
  2. Amlodipine in the WHO Essential Medicines List

What side effects are possible with Amlocor?

Possible Side Effects and Safety Information

The safety profile of Amlocor (Amlodipine) is based on adverse reaction data documented by regulatory authorities, classifying effects by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reaction is peripheral edema (ankle swelling), officially classified as Very Common (occurring in 1 in 10 patients or more). Other effects classified as Common (occurring in up to 1 in 10 patients) include headache, dizziness, somnolence (drowsiness), palpitations, and flushing. Less frequent effects classified as Uncommon include insomnia, mood changes, muscle cramps, and hypotension.

Serious Adverse Reactions and Safety Constraints

The official labeling notes that serious adverse reactions may include the potential for increased angina or acute myocardial infarction, particularly when treatment is initiated or the dose is increased. Other rare but serious events documented in post-marketing reports include hepatitis, jaundice, and severe allergic reactions such as angioedema.

Safety limitations specify that caution is required in patients with conditions like severe aortic stenosis or severe hypotension.

Population-Specific Safety Notes

The regulatory profile includes specific notes for certain patient groups. Individuals with hepatic impairment (impaired liver function) may experience decreased clearance of the medicine, which increases systemic exposure. For older adults, decreased clearance is also observed, indicating a need for careful assessment. The safety of Amlocor use during pregnancy and lactation has not been established in human studies.

Overdose and Emergency Response

Amlocor Overdose and When to Seek Help

The official regulatory profile for Amlocor (amlodipine) defines overdosage by its severe cardiovascular manifestations, which are an extreme exaggeration of the drug’s intended effect.

Documented Overdose Presentations Overdosage is primarily documented to result in excessive peripheral vasodilation leading to marked hypotension (severely low blood pressure). A compensatory reflex tachycardia may also be present as the body attempts to counteract the profound drop in blood pressure. The severe, life-threatening outcomes officially listed include the potential for shock and cardiovascular collapse.

Mandated Emergency Action Due to the risk of severe outcomes, immediate medical attention or contact with emergency services is mandated for all cases of suspected overdose. Active clinical and respiratory monitoring must be initiated immediately upon presentation.

Official Management and Monitoring Management is strictly limited to symptomatic and supportive measures. The official regulatory profile states explicitly that no specific antidote for amlodipine is known. Procedural steps may include gastric decontamination, such as the use of activated charcoal, if ingestion was recent. Continuous monitoring of vital signs is required. Furthermore, a specific regulatory constraint notes that due to the drug's extensive protein binding, amlodipine is not dialyzable, and an extended overnight hospital observation/stay may be necessary due to the drug's prolonged elimination half-life.

Therapeutic Uses of Amlocor

What Amlocor Treats: Main Uses and Benefits

Amlocor (Amlodipine) is used for the management of two distinct, yet related, cardiovascular conditions: high blood pressure and specific types of chest pain.

The medication is applied in addressing conditions involving episodic or fluctuating manifestations, such as various forms of Angina Pectoris, including chronic stable angina and the intense manifestations of vasospastic angina, as well as the long-term, systemic challenge of Hypertension. This use helps address symptom clusters that may become intense or disruptive, specifically the chest discomfort associated with heightened physiological activity. Amlocor plays a role in managing symptoms related to systemic imbalance by contributing to reducing the risk of cardiovascular events, including complications affecting the heart and brain.

“This medication supports the patient during difficult episodes by assisting with maintaining functional stability and easing the overall symptom load during periods of heightened discomfort.”

In patients with structurally documented Coronary Artery Disease, Amlocor is considered relevant when supportive symptom management is appropriate. This supports the management of the symptomatic burden in situations with significant discomfort, and the medication may also assist with managing symptoms in ways that support the patient's long-term care plan.


Quick Fact: Relief for Elevated Physiological Stress


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Official regulatory labeling strictly defines who can and cannot use Amlocor (Amlodipine). The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to amlodipine or to other drugs of the dihydropyridine class. Absolute contraindications also include conditions of circulatory failure, such as severe hypotension (very low blood pressure) and shock (including cardiogenic shock).

Age-Related and Conditional Use

Use is approved for adults and for pediatric patients ages 6 to 17 years for the treatment of hypertension. However, the safety and efficacy have not been established in children younger than 6 years of age.

Patients with hepatic impairment (liver disease) are classified as a restricted-use population and must be treated with caution due to decreased drug clearance. Caution is also required for patients with severe heart failure or severe aortic stenosis. For pregnancy, safety has not been established, and the drug is known to be excreted in human milk during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory documentation for Amlocor (Amlodipine) details specific interaction patterns primarily related to its metabolism and effects on co-administered medicines, structured around pharmacokinetic and pharmacodynamic outcomes.


Pharmacokinetic and Metabolic Interactions

A major focus is the CYP3A4 metabolic pathway. Co-administration with strong or moderate CYP3A4 inhibitors (such as Itraconazole or Clarithromycin) significantly increases the systemic exposure (plasma concentration) of Amlocor, as stated in official labeling. Conversely, use with potent CYP3A4 inducers (e.g., Rifampicin, St. John's wort) may reduce Amlocor's plasma concentration.

Amlocor also alters the clearance of other medicines. The official label dictates a mandatory dose restriction for Simvastatin, specifying that the Simvastatin dose must not exceed 20 mg daily due to increased systemic exposure. Amlocor may also increase the blood concentrations of immunosuppressants such as Tacrolimus and Cyclosporine.


Pharmacodynamic Effects and Restrictions

Pharmacodynamic effects include the potential for an additive hypotensive effect when combined with other blood pressure-lowering agents. Co-administration with Grapefruit or Grapefruit Juice is not recommended as this may increase Amlocor's bioavailability. A specific avoidance is noted for intravenous Dantrolene in susceptible patients due to hyperkalemia risk. Interaction potential is also amplified in patients with severe hepatic impairment due to reduced clearance.

Mechanism of Action

Amlocor is a dihydropyridine calcium channel antagonist, inhibiting the transmembrane influx of calcium ions (Ca^2+) primarily into vascular smooth muscle cells. The biological target is the alpha1C subunit of the voltage-dependent L-type calcium channels (L-channels).

The drug molecule interacts with and blocks these channels, reducing the intracellular concentration of calcium. This intracellular Ca^2+ reduction diminishes the binding of calcium to calmodulin, leading to a decrease in the activity of myosin light-chain kinase (MLCK). Reduced MLCK activity results in decreased phosphorylation of the myosin light chain.

This molecular change interrupts the actin-myosin cross-bridge cycling necessary for smooth muscle contraction, inducing smooth muscle relaxation. This downstream cascade results in arteriolar vasodilation, specifically in peripheral and coronary vascular beds. The system-level physiological consequence is a reduction in peripheral vascular resistance, which modulates systemic arterial pressure. Additionally, the coronary vasodilation increases coronary blood flow.

Dosage and Administration Information

Amlocor (Amlodipine) is supplied as an oral tablet for administration by mouth, which constitutes the route for this single-ingredient formulation. The medication is typically administered on a once-daily schedule to maintain consistent drug levels over 24 hours. To support treatment consistency, the tablet may be taken with or without food and is generally consumed at the same time each day.


Usage begins with a standard regimen. For most adults, the usual initial dose is 5 mg once daily, though some patients may begin at 2.5 mg. The dosage may be subsequently increased, but should not exceed the maximum recommended dose of 10 mg once daily. Any decision to adjust the dose is typically preceded by an observation period of 7 to 14 days to assess the response before titration is considered. This protocol establishes the structured approach for long-term maintenance.


Specific dosing considerations apply to particular populations. Older adults or patients with hepatic impairment typically initiate therapy at the lower dose of 2.5 mg daily due to potential differences in drug clearance, requiring a cautious, slower titration approach. Conversely, for patients with renal impairment, prescribing information indicates that no dose adjustment is required. In the pediatric population (ages 6 to 17) being treated for hypertension, the maximum daily dose is restricted to 5 mg. If a dose is missed, the general protocol is to take the dose as soon as it is remembered; however, two doses are not to be taken simultaneously to compensate for the skipped dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amlocor


Evidence for Use in Managing High Blood Pressure (Hypertension)

The most extensive body of evidence for Amlocor was studied in the context of high blood pressure in adults. This research relies primarily on Randomized Controlled Trials (RCTs) and supporting systematic reviews and meta-analyses. Measurements studies monitored included changes in systolic and diastolic blood pressure readings. Longer-term research explored how the medicine was associated with patterns in the occurrence of major cardiovascular events over follow-up periods lasting several years. Studies reported measurements describing a change in blood pressure readings. Research tracking long-term outcomes provides context, with data showing patterns related to the frequency of cardiovascular events across the studied groups.


Evidence for Use in Managing Angina Pectoris

Amlocor was evaluated in specific research contexts involving conditions characterized by fluctuating or episodic manifestations of chest pain, known as angina. This includes studies on chronic stable angina and vasospastic angina. The research examined outcomes related to physical discomfort, primarily monitoring the frequency of chest pain episodes and the time until symptoms recurred during assessments. Trials documented changes in the self-reported frequency of angina episodes in the observed populations. Evidence is limited in fully describing symptomatic responses across all ages of adults or varying levels of disease severity.


What the Research Indicates is Still Unknown or Uncertain

While Amlocor was studied for its primary indications, research is ongoing in some areas and evidence is not yet complete in others. Research describes group patterns observed in studies, but does not determine individual outcomes. Limited information is available to make direct comparisons between Amlocor and every single other medication developed since its approval. The data are still emerging to fully detail the long-term observation of the medicine over extended periods spanning multiple decades in various populations. Therefore, the evidence highlights what is known — and what is still uncertain — about the full scope of Amlocor's use in various complex health scenarios.

Key Studies & References Coronary Artery Disease: Angina Pectoris and Myocardial Infarction Management Guidelines (Representative Guideline)

Frequently Asked Questions (FAQ)

Common questions about Amlocor (FAQ)


Q: Is Amlocor a water pill or a blood pressure medicine?

A: Amlocor (amlodipine) is classified as a calcium channel blocker, which is a type of medicine used to relax blood vessels and lower blood pressure. It is not classified as a diuretic, which is the type of drug commonly referred to as a water pill.


Q: Does Amlocor make you tired during the day?

A: Official prescribing information notes that adverse reactions reported during clinical trials include somnolence (drowsiness) and fatigue (tiredness). If you experience these effects, it is documented that they are reported to be related to the use of this medicine.


Q: Is it common for Amlocor to cause ankle swelling?

A: Yes, peripheral edema, which is swelling typically seen in the ankles or feet, is documented in official sources as the most common adverse reaction. This side effect is classified as Very Common, meaning it has been reported to affect 1 out of 10 people or more.


Q: Can I stop taking Amlocor if my blood pressure is normal now?

A: Regulatory patient information indicates that this medication is typically used for the long-term control of high blood pressure, not as a cure. Patients are generally advised to continue taking it as prescribed for sustained periods. Any change in the regimen is a decision to be made by a healthcare provider.


Q: What foods or drinks should be limited while taking Amlocor?

A: Official drug documents advise against the co-administration of Grapefruit or Grapefruit Juice with Amlocor. This is due to the potential for grapefruit to increase the amount of medicine absorbed into the body.


Q: Are there any studies looking at the long-term effects of Amlocor?

A: Yes, official prescribing documents reference longer-term research that explored the medicine's association with patterns in the occurrence of major cardiovascular events. This research involved follow-up periods lasting several years.


Q: Can Amlocor make certain side effects from other medications worse?

A: Regulatory documents note that when Amlocor is combined with other agents used to lower blood pressure, there is a possibility of an additive hypotensive effect. This combination may result in an additional reduction in blood pressure.


Q: Does Amlocor have different effects on men versus women?

A: Clinical data summaries have specifically described that the adverse reaction of peripheral edema (ankle swelling) may occur at a higher rate in women compared to men.


Q: What are the general expectations for blood pressure reduction when starting Amlocor?

A: The medicine is designed for once-daily dosing, with its blood pressure-lowering effectiveness typically maintained for at least 24 hours. To fully determine a patient's response, an observation period of 7 to 14 days is often used before considering any dosage changes.


Q: Do studies suggest Amlocor has benefits beyond just lowering blood pressure?

A: Yes, in addition to managing high blood pressure, official studies support the use of Amlocor for the symptomatic treatment of certain types of angina (chest pain). This includes both chronic stable and vasospastic angina.


Q: Is Amlocor widely accepted by major health organizations?

A: The active substance in Amlocor is included on the World Health Organization’s (WHO) Model List of Essential Medicines. This inclusion describes its recognized importance for the sustained management of chronic conditions involving vascular tone in adults.


Q: Can Amlocor affect a person's mood?

A: Official product information lists mood changes and insomnia (difficulty sleeping) among the adverse reactions. These are classified as Uncommon side effects, which means they have been reported to occur in up to 1 in 100 people.


Q: Are there any known severe allergic reactions to Amlocor?

A: Yes, regulatory documents mention that rare but serious events documented in post-marketing reports include severe allergic reactions. These include conditions such as angioedema (swelling of the face, lips, tongue, or throat) and hepatitis.


Q: Is Amlocor a drug that requires regular blood tests?

A: Official guidance does not state a general requirement for blood tests for all users. However, regulatory documents describe that caution and potential dose assessment are warranted for patients with hepatic impairment (liver disease) due to potential changes in how the body clears the drug.


Q: How long does it usually take for Amlocor to start working?

A: To fully assess a patient's full response to the medication, an observation period of 7 to 14 days is often needed. This period allows the treating healthcare professional to determine if a dose adjustment may be necessary.


Q: Do you have to take Amlocor for the rest of your life?

A: As a long-term maintenance therapy for chronic conditions like high blood pressure, the drug is typically taken once daily for sustained periods. The duration of treatment is established by a healthcare provider as part of the patient's individual treatment plan.


Q: Why do official documents state that Amlocor is used for chest pain (angina)?

A: Official documents describe that Amlocor acts as a peripheral arterial and coronary vasodilator. This means it helps widen blood vessels, which increases blood supply to the heart and helps relieve the symptoms of chest pain associated with angina.


Q: Is Amlocor safe for older people to take?

A: Official guidance permits the use of Amlocor in older adults, but it suggests initiating therapy at the lower dose of 2.5 mg daily. This cautious approach is described due to the potential for decreased drug clearance in this population.


Q: What is the recommended time of day to take Amlocor?

A: The approved schedule is for once-daily administration. Official documents advise that the tablet be consumed at the same time each day in order to maintain consistent drug levels throughout the 24-hour period.


Q: Does Amlocor affect cholesterol levels?

A: While Amlocor is not a cholesterol-lowering drug, official documents mandate a dose restriction for the medicine Simvastatin when taken concurrently. This is due to Amlocor’s reported effect on increasing the exposure of Simvastatin in the body.


Q: Are there any high-level warnings about Amlocor for women who might become pregnant?

A: Official regulatory documents state that the safety of Amlocor use during pregnancy and lactation (breastfeeding) has not been established in human studies. This information is detailed in the population-specific safety notes.

How should Amlocor be stored and disposed of?

Amlocor (amlodipine besylate) tablets must be stored according to specific regulatory conditions to maintain product stability and safety.

Official Storage Requirements

The tablets require storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted brief temperature excursions between 15 C and 30 C.

Storage Factor Requirement
Temperature Controlled Room Temperature
Container Protection Keep in original, tightly closed container
Environmental Protection Protect from moisture and light
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Official labeling instructs that any unused or expired Amlocor must be disposed of according to local regulatory requirements. The product should not be discarded into household waste or flushed into wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlocor found in:

A-Z Index: